193965-30-9

Basic information

• Product Name: 5-METHOXYBENZO[B]THIOPHENE-2-BORONIC ACID
• Synonyms: 5-METHOXYBENZO[B]THIOPHENE-2-BORONIC ACID;5-methoxybenzo[b]thiophen-2-ylboronic acid
• CAS NO: 193965-30-9
• Molecular Formula: C₉H₉BO₃S
• Molecular Weight: 208.05
• Mol File: 193965-30-9.mol

Chemical Properties

• Boiling Point: 423.1 °C at 760 mmHg
• Flash Point: 209.7 °C
• Appearance: /
• Density: 1.35 g/cm³
• Vapor Pressure: 6.51E-08mmHg at 25°C
• Refractive Index: 1.64
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-METHOXYBENZO[B]THIOPHENE-2-BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXYBENZO[B]THIOPHENE-2-BORONIC ACID(193965-30-9)
• EPA Substance Registry System: 5-METHOXYBENZO[B]THIOPHENE-2-BORONIC ACID(193965-30-9)

Safety Data

• Hazardous Substances Data: 193965-30-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Methoxybenzo[b]thiophene-2-boronic acid is used as a reagent for the synthesis of dibasic benzo[b]thiophene derivatives. These derivatives represent a novel class of active site directed thrombin inhibitors, which are crucial in the development of new drugs for the treatment of various thrombotic disorders. The compound plays a significant role in structure-activity studies on conformationally restricted C3-side chains, which are essential for understanding the interaction between thrombin and its inhibitors.

InChI:InChI=1/C9H9BO3S/c1-13-7-2-3-8-6(4-7)5-9(14-8)10(11)12/h2-5,11-12H,1H3

Upstream product

• 20532-30-3 5-methoxybenzothiophene 

Downstream Products

• 193965-31-0 5-methoxy-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophene 
• 193965-32-1 4-Fluorophenyl 5-Methoxy-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophen-3-yl Ketone 
• 1097776-88-9 ethyl 4-(5-methyloxy-1-benzothien-2-yl)benzoate 
• 1097778-18-1 ethyl 3-(5-methyloxy-1-benzothien-2-yl)benzoate 

Relevant articles and documents

C-benzo five-membered heteroaromatic aryl glucoside derivative as well as preparation method and application thereof

The invention discloses a C-benzo five-membered heteroaromatic aryl glucoside derivative shown in the general formula (I) (in the description), a preparation method of the derivative or an intermediate of the derivative, as well as application of the derivative. In the general formula (I), R, R1, R2, R3, R4, X and Y are defined in the description. The C-benzo five-membered heteroaromatic aryl glucoside derivative is novel in structure, has quite strong inhibitory activity on SGLT-2, has high selection ratio for SGLT-1 and SGLT-2, and can be used for preparing drugs for treating and preventing diseases relevant to SGLT-2.

FARNESOID X RECEPTOR AGONISTS

The present invention relates to famesoid X receptors (FXR, NR1H4) FXR is a member of the nuclear receptor class of ligand-activate transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R14; with R1, R2, R3, R4, R5, R6, R7, R8, and R14 defined herein.

Antithrombotic diamines

This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.